LHLuis R. Hoyos

Luis R. Hoyos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luis R. Hoyos has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Gustavo Vilchez

    Department of Obstetrics and Gynecology, University of Missouri-Kansas City School of Medicine, 2310 Holmes St. STE 713, Kansas City, MO, 64108, USA.

    2 shared publications
  • Awoniyi O. Awonuga

    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Wayne State University/Hutzel Women's Hospital, Detroit, MI, USA

    1 shared publication
  • Javier Rodriguez-Kovacs

    Department of Obstetrics and Gynecology, Wayne State University/Hutzel Women's Hospital, 3990 John R, 7-Brush N, Mail Box 165, Detroit, MI, 48201, USA

    1 shared publication
  • Jay M. Berman

    Wayne State University School of Medicine, Detroit, Michigan (Dr. Berman)

    1 shared publication
  • Jocelyn Leon-Peters

    Department of Obstetrics & Gynecology, Wayne State University/Hutzel Women's Hospital, 3990 John R, 7-Brush N, Mail Box 165, Detroit, MI, 48201, USA

    1 shared publication
  • Maria C. Maldonado

    Department of Obstetrics and Gynecology, Wayne State University/Detroit Medical Center, 3990 John R, 7-Brush N, Mail Box 165, Detroit, MI, 48201, USA

    1 shared publication

Latest Publications

  • Morbid obesity and outcome of ectopic pregnancy following capped single-dose regimen methotrexate

    by Luis R. Hoyos, Mokerrum Malik, Marvin Najjar, Javier Rodriguez-Kovacs, Mazen Abdallah, Gustavo Vilchez, Awoniyi O. Awonuga

    Evaluate whether morbid obesity influenced resolution, number of doses or ultimately surgical management of tubal ectopic pregnancy (TEP) when treated with single-dose regimen methotrexate (SDR-MTX) capped at 100 mg. Retrospective cohort study of patients with a diagnosis of TEP who underwent MTX treatment from 2000 to 2013. Patients were excluded if initial β–hCG 2 with a capped maximum of 100 mg. Patients were divided based on their BMI (2). Demographic variables, β–hCG before treatment, maximum diameter of ectopic size, embryonic heart tones, decrease of β–hCG, need for additional MTX doses and surgery despite treatment were recorded and compared among the groups. 151 women were included in the study, 89.4% (135/151) non-morbidly obese and 10.6% (16/151) morbidly obese. No differences in age distribution, ethnicity, pre-treatment presence of embryonic heart tones, maximum diameter of ectopic size ≥35 mm and β–hCG ≥5000 mIU/ml were found. Following treatment, the proportion of patients with at least an 80% decrease in their β–hCG levels or need for surgery were similar, however, morbidly obese patients were significantly more likely [11/134 vs. 5/16, OR 5.1 (1.5–17.3, p = 0.015)] to require an additional MTX dose. Among patients with TEP, morbidly obese patients were five times more likely to require an additional dose compared to non-morbidly obese when SDR-MTX capped at 100 mg was used for medical management.


  • Risk of neonatal mortality according to gestational age after elective repeat cesarean delivery

    by Gustavo Vilchez, Luis R. Hoyos, Maria C. Maldonado, Moraima Lagos, Michael Kruger, Ray Bahado-Singh

    Despite the well-known neonatal morbidity risks after elective cesarean deliveries performed before 39 weeks, there are scarce data regarding mortality risks. The objective of this study was to calculate the risk of neonatal mortality after elective repeat cesarean delivery (ERCD) by gestational age. The Linked Birth–Infant Death Data Files from the Vital Statistics Data of the Center for Disease Control and Prevention of the U.S. from 2004 to 2008 were analyzed. Only ERCD cases were included. Early death (<7 days), neonatal death (<28 days), and infant death (<1 year) were evaluated. A logistic regression model was used to calculate odds ratios. Cases delivered at 37–41 weeks were studied with 40 weeks as reference. A total of 483,052 cases were included for analysis. The distribution of rates and odds ratios for infant, neonatal and early death was U-shaped with the nadir at 39 weeks. There was a statistically significant increase in early death at 37 compared to 40 weeks’ gestation [OR (95 %) CI = 1.929(1.172–3.176)]. No statistical increase was found in any of the other mortality risks. There is an increased risk in early death with ERCD performed at 37 weeks. Our study provides evidence of neonatal harm beyond the reported morbidity risks.